<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02336282</url>
  </required_header>
  <id_info>
    <org_study_id>ALLSTIM</org_study_id>
    <secondary_id>NCI-2015-00050</secondary_id>
    <nct_id>NCT02336282</nct_id>
  </id_info>
  <brief_title>Treatment for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Feasibility and Efficacy of Transcranial Direct Current Stimulation (tDCS) and Cognitive Training for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A common and potentially debilitating late effect of childhood cancer treatment is
      neurocognitive impairment, frequently in the domain of executive dysfunction, which can limit
      educational attainment, employment, and quality of life. Among the survivors of childhood
      acute lymphoblastic leukemia (ALL) in the SJLIFE cohort, the frequency of executive function
      impairment has been shown as high as 58.8%, with moderate to severe impairment as high as
      33.5%, and risk for impairment increased with time from diagnosis. Given the potential of
      pervasive impact of neurocognitive impairment on daily life, interventions directed at
      reducing neurocognitive dysfunction among childhood cancer survivors with long-term follow-up
      are needed. This study examines the potential feasibility and efficacy of a novel
      intervention to improve executive function.

      Primary Objectives:

        -  To evaluate the feasibility of a home-based intervention using Transcranial Direct
           Current Stimulation (tDCS) and cognitive training in adult survivors of childhood ALL
           participating in the SJLIFE protocol at St. Jude Children's Research Hospital (SJCRH).

      Secondary Objectives:

        -  To estimate the efficacy of a tDCS intervention paired with cognitive training.

        -  To explore the short-term effect of tDCS on measures of executive function among adult
           survivors of childhood ALL participating in the SJLIFE protocol
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      tDCS is a form of non-invasive brain stimulation and is a potentially useful tool to enhance
      cognitive function. This study uses an at-home intervention of tDCS and cognitive training
      and examines its potential usefulness at improving executive function in ALL survivors.

      Investigators will use tDCS to apply a low electrical current to the participant's scalp in
      the area of the brain associated with fluent and flexible thinking. The current may make that
      area of the brain work better for a short period of time. During this time, the participant
      will play computer games designed to train the brain to work more fluently flexibly.
      Researchers at St. Jude Children's Research Hospital want to see if pairing the electrical
      stimulation with the brain games at home is a feasible method to improve cognitive abilities
      in long-term survivors of childhood ALL.

      In the first part of this study, the short-term effect of tDCS intervention will be evaluated
      in the clinical setting using a randomized cross-over trial. The survivors will be randomized
      to receive either the tDCS intervention or Sham on day 1, with the other treatment given on
      day 2. Neurocognitive testing will be conducted within two hours of completing stimulation
      each day.

      In the second part of this study, the feasibility and potential efficacy of
      self-administration of the tDCS intervention paired with cognitive training will be evaluated
      over 5 weeks. Research participants will be taught to use the mobile tDCS device and will be
      provided one to take home. The device will be programmed by the investigators in advance to
      control the intensity and duration of the stimulation. The research participants will use the
      device twice per week as directed. Within two hours of completing each tDCS session
      participants will complete 20 minutes of cognitive training using a mobile app installed on
      an iPad. Neurocognitive testing will be conducted pre- and post- intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2015</start_date>
  <completion_date type="Actual">June 9, 2017</completion_date>
  <primary_completion_date type="Actual">June 9, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who successfully complete 5 sessions out of 10</measure>
    <time_frame>5 weeks after participant enrollment</time_frame>
    <description>The trial will be considered feasible if at least 50% of the survivors are able to complete 5 sessions (tDCS along with cognitive stimulation) successfully out of 10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive testing scores</measure>
    <time_frame>Baseline at participant enrollment and 5 weeks after baseline</time_frame>
    <description>The improvement in cognitive testing scores from baseline to 5-week follow up will be done using matched pair one sample t-tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in scores on the NIH Toolbox Card Sort task</measure>
    <time_frame>After active and sham interventions administered on day one and day two of the trial</time_frame>
    <description>The improvement in the scores on the NIH Toolbox Card Sort task between tDCS and sham, will be done using matched pair one sample t-test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in scores on the NIH Toolbox Flanker task</measure>
    <time_frame>After active and sham interventions administered on day one and day two of the trial</time_frame>
    <description>The improvement in the scores on the NIH Toolbox Flanker task between tDCS and sham, will be done using matched pair one sample t-test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in scores on the NIH Toolbox Working Memory task</measure>
    <time_frame>After active and sham interventions administered on day one and day two of the trial</time_frame>
    <description>The improvement in the scores on the NIH Toolbox Working Memory task between tDCS and sham, will be done using matched pair one sample t-test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>tDCS on Day 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On day one, participants will be randomized to receive the transcranial Direct Current Stimulation (tDCS) intervention. On day two, participants receive sham intervention.
On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.
In the second phase of the trial, participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive assessment will be conducted pre- and post-intervention using remote assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tDCS on Day 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On day one, participants will be randomized to receive sham intervention. On day two, participants receive the transcranial Direct Current Stimulation (tDCS) intervention.
On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.
The second phase of the trial will be conducted the same as for participants in the tDCS on Day 1 arm. Participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive testing will be conducted pre- and post-intervention using remote assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial Direct Current Stimulation (tDCS)</intervention_name>
    <description>transcranial Direct Current Stimulation (tDCS) involves modulation of cerebral cortex excitability by the application of weak direct current to the scalp. tDCS is a technique that applies safe, low level direct current through large pads on the scalp to stimulate the underlying brain region, with current level &lt; 0.10 C/cm2. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.</description>
    <arm_group_label>tDCS on Day 1</arm_group_label>
    <arm_group_label>tDCS on Day 2</arm_group_label>
    <other_name>tDCS</other_name>
    <other_name>Transcranial Electrical Stimulation 1x1 Clinical Trials Device</other_name>
    <other_name>Soterix Transcranial Direct Current Stimulator Clinical Trials</other_name>
    <other_name>Soterix Medical Device 1x1-CT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>The sham intervention will be used in both arms with one arm receiving the sham intervention on day 1 and the other receiving the sham intervention on day 2. The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramp up and no intervention is provided. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.</description>
    <arm_group_label>tDCS on Day 1</arm_group_label>
    <arm_group_label>tDCS on Day 2</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive Assessment</intervention_name>
    <description>Three tests will be used to evaluate cognitive function: Dimensional Change Card Sort Test, Flanker Inhibitory Control and Attention Test, and List Sorting Working Memory Test. These measures have a computerized format and are nationally standardized.
The Gray Oral Reading Test measures reading comprehension. Participants are asked to read a set of passages and recall specific details from the stories.
The Woodcock Johnson Understanding Directions measures listening comprehension. Participants listen to a series of complex instructions, then follow the directions by pointing to various objects in a colored picture.</description>
    <arm_group_label>tDCS on Day 1</arm_group_label>
    <arm_group_label>tDCS on Day 2</arm_group_label>
    <other_name>NIH Toolbox Cognitive Battery</other_name>
    <other_name>Gray Oral Reading Test</other_name>
    <other_name>Woodcock Johnson Understanding Directions</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brain Games Stimulation</intervention_name>
    <description>Cognitive exercises using the Lumosity Brain Games program will be used simultaneously with the tDCS intervention. Participants will be asked to engage in training for 20 minutes a day, two days per week over 5 weeks. This program involves cognitive exercises designed to enhance executive function and processing speed.</description>
    <arm_group_label>tDCS on Day 1</arm_group_label>
    <arm_group_label>tDCS on Day 2</arm_group_label>
    <other_name>Lumosity Brain Games</other_name>
    <other_name>www.lumosity.com</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current St. Jude LIFE (SJLIFE) Protocol Participant

          -  Long term survivor of acute lymphoblastic leukemia (ALL)

          -  Currently â‰¥ 18 years of age

          -  Wi-Fi internet access at home

          -  History of executive dysfunction, documented by neurocognitive testing, and defined as
             having an age-adjusted standard score &lt;20th percentile on Trail Making Test Part B,
             Verbal Fluency, or Digit Span Backward.

          -  History of self-reported executive dysfunction in daily life, defined as having a
             standardized score &lt;20th percentile on BRIEF Initiate, Shift, or Working Memory
             domains OR having scored &lt;20th percentile on the Childhood Cancer Survivor Study
             Neurocognitive Questionnaire Task Efficiency of Memory domains.

          -  Participant is able to speak and understand the English language.

        Exclusion Criteria:

          -  Any survivor with full scale intelligence quotient (IQ) &lt;80

          -  Currently on stimulants or other medications intended to treat cognitive impairment

          -  History of seizures

          -  No implanted medical devices or implanted metal in the head

          -  Currently pregnant or planning to become pregnant.

          -  Inability or unwillingness of research participant or legal guardian/representative to
             give written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Krull, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>January 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2015</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult survivor of acute lymphoblastic leukemia</keyword>
  <keyword>Executive dysfunction</keyword>
  <keyword>Transcranial direct current stimulation</keyword>
  <keyword>Cancer prevention and control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>April 5, 2018</submitted>
    <returned>May 7, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

